Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
European Journal of Gastroenterology & Hepatology|June 27, 2025
Identification of high-risk group for diabetes-associated hepatocellular carcinoma using noninvasive test for liver fibrosisKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
Eclinicalmedicine|September 8, 2023
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysisAnand V Kulkarni, Harshvardhan Tevethia, Karan Kumar, et al.
Oncology|March 30, 2025
Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab TherapyKhanh Van Nguyen, Kosuke Matsui, Hisashi Kosaka, et al.
Oncology|November 29, 2021
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment EraAtsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Hepatology Communications|August 29, 2025
Carbon-ion radiotherapy achieves outcomes equivalent to surgical resection for hepatocellular carcinomaTakeshi Hatanaka, Kei Shibuya, Satoru Kakizaki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2016
Clinical and virological features of acute hepatitis E in Gunma prefecture, Japan between 2004 and 2015Yuichi Yamazaki, Atsushi Naganuma, Yosuke Arai, et al.
Journal of Gastroenterology|June 28, 2022
Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade)Kazuya Kariyama, Atsushi Hiraoka, Takashi Kumada, et al.
Acta Medica Okayama|October 28, 2024
Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular CarcinomaYuichi Hirano, Kazuhiro Nouso, Kazuya Kariyama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 24, 2017
Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirinKen Sato, Atsushi Naganuma, Tamon Nagashima, et al.
Hepatology International|February 28, 2025
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in JapanShigeo Shimose, Issei Saeki, Takanori Ito, et al.
Pageof 17